INTRODUCTION
Since the discovery and purification of the first hematopoietic cytokines over two decades ago, ex vivo culture techniques have been developed for stem cell expansion and gene therapy applications. The ability to expand HSPC could widen the availability and improve the efficacy of cord blood (CB) transplantation, speed recovery from cytopenias after transplantation, and ensure engraftment in mismatched or non-myeloablative allogeneic transplantation. Genetic manipulation of HSPC with retroviral vectors requires ex vivo stimulation with cytokines to maintain viability and to stimulate progression through the cell cycle, allowing nuclear membrane dissolution and vector access to chromosomal DNA. Genetic modification of HSPC with lentiviral vectors, despite less reliance on cell cycle progression for vector access to chromatin, also requires cytokine stimulation for efficient transduction(1;2). However, a loss of in vivo repopulating stem cell function after even relatively brief culture in stimulatory cytokines has been demonstrated in murine studies (3;4) , the rhesus autologous transplantation model (5) , and non-obese diabetic/severe combined immunodeficiency (NOD/SCID) mouse studies using human CB cells or mobilized peripheral blood (MPB) stem cells(6;7).
The mechanism for this phenomenon remains incompletely understood, but it has been proposed to result from changes in the expression or function of cell surface molecules including chemokine receptors such as CXCR4, integrins such as very late antigen-4 (VLA-4), tetraspanins such as CD82, selectins, or leukosialins (8) . These molecules function in the complex processes of homing and engraftment to the bone marrow (BM) by participating in the intimate physical contact of the HSPC with the osteoblastic and endothelial components of the microenvironment (9) (10) (11) . Using live cell
For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From imaging approaches, we previously showed that HSPC make prolonged contact with the osteoblastic surface via a polarized membrane domain enriched in prominin 1, VLA-4, and tetraspanin proteins (12) .
Tetraspanins are part of a large family of evolutionarily conserved fourtransmembrane domain proteins. They facilitate the assembly of specialized molecular aggregates on plasma and intracellular membranes known as tetraspanin-enriched microdomains (TEM) that consist of tetraspanins as well as other membrane and cytosolic proteins such as receptor tyrosine kinases, integrins, and adaptor proteins that are integral to signaling cascades. Depending on the nature of the interacting proteins, tetraspanins have been implicated in the control of cellular migration, adhesion, and signaling (13) (14) (15) (16) . CD82 has been shown to be an important member of the tetraspanin superfamily of glycoproteins and appears to function by modulating the levels, trafficking or activity of its interacting partners in the TEM. In the context of cancer, CD82, also known as Kai1, associates with integrins on the surfaces of various tumor cells, and its expression is linked to metastasis suppression (17) . CD82 can also be found in cells of the immune system (18) and has been shown to be highly expressed on the majority (up to 95%) of CD34+ cells isolated from healthy BM, CB and MPB samples while only moderate expression was detected on normal mature peripheral blood cells (19) . Similarly, CD82 was overexpressed in CD34+ blasts isolated from patients with acute myeloid leukemia (AML), and in leukemic cells from patients with chronic myeloid leukemia (CML) in accelerated or blastic phase, and chronic lymphocytic leukemia (CLL) (19) .
These observations suggested a role of CD82 in normal and malignant hematopoiesis.
Analogous to normal HSPC, it has been proposed that leukemic cells are hierarchically (20) (21) (22) (23) . These rare cells are enriched in the CD34+ cell population and rely on interactions with the BM microenvironment to control their self-renewal and differentiation (24) (25) (26) (27) (28) .
In this study we analyzed the distribution of CD82 as an indicator of domain polarity in normal and malignant CD34+ cells, and investigated the functional significance of this organized membrane domain for homing and engraftment of HSPC to the BM microenvironment.
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MATERIALS AND METHODS

Patients and healthy donors
Cells from patients with AML (n=5), CML (n=1) and ALL (n=1) were obtained from peripheral blood, BM or leukapheresis products before chemotherapy treatment or hematopoietic stem cell transplant. Human CD34+ cells were also collected from healthy donors who received G-CSF (10µg/Kg, Filgrastim) for 5 days, given as a single daily 
Transplantation of normal and leukemic human hematopoietic cells into immunedeficient mice
NSG mice were purchased from Jackson Laboratories (Bar Harbor, ME) and maintained at the NIH under specific pathogen-free conditions. For homing studies, eight to tenweek-old mice (n=3-5 mice/group) were sublethally irradiated (300 cGy), transplanted intravenously with 1x10 6 G-CSF mobilized CD34+ cells from healthy donors, or 1x10 The animal experiments were approved by the Animal Care and Use Committee of the National Institutes of Health.
Analysis of human cell homing and engraftment
Six bones were collected from each mouse for analysis of human cell homing and engraftment in the murine BM. In select mice, homing was also examined in the 
Adhesion assay
The osteoblastic cell line SaOS-2 (American Type Culture Collection) was prepared for adhesion assays according to manufacturer's recommendations by washing twice with PBS. CD34+ cells were introduced to monolayers at a final concentration of 10,000 cells/100ul/well and allowed to incubate for 4 hours at 37 o C in X-Vivo media. The nonadherent cells were removed in three subsequent washes and counted using a hemocytometer to determine the number of adherent cells remaining in each well. As a control, osteoblast monolayers alone were washed and released cells were counted to identify any background contamination. 
Function blocking CD82 antibody assay
Statistics
Data were analyzed using the unpaired Student's t test using Sigma Plot or KaleidaGraph software. All of the statistical tests were 2 sided. A P value of 0.05 was considered to be statistically significant.
RESULTS
A polarized membrane domain is found on normal HSPC
To explore membrane domain organization and its regulation in actively cycling cultured normal HSPC, we first examined the baseline surface distribution of various adhesion molecules on non-cultured human MPB CD34+ cells from healthy donors using confocal microscopy. Scoring at least 100 cells, we found that VLA-4 ( Fig. 1A) , CXCR4
( Fig. 1B) , and CD82 (Fig. 1C) , displayed a polarized distribution on the plasma membrane. The polarized localization of these markers was specific because other surface markers, CD45 ( At baseline (day 0), the majority of CD34+ cells (84%) were in the G0 phase of the cell cycle ( Fig. 2A) , up to 2.5% of human cells were detected in the mouse BM 16
hours after transplantation (Fig. 2B) , and 55% of the cells had polarized domains (Fig.   2C ). After 4 days in stimulatory cytokines, few cells (0.4%) remained quiescent in G0
( Fig. 2D) , only rare cells (0.1%) homed to the mouse BM (Fig. 2E) , and while all cells continued to express CD82 as assessed by flow cytometry (Supplemental Figure 1) , only 12% of the cells maintained their domain polarity (Fig. 2F) . VLA-4 distribution was similar to that of CD82 with a polarized enrichment of membrane VLA-4 at Day 0 that was mostly redistributed throughout the plasma membrane at Day 4 (Supplemental Figure 2 ). Cells cultured in SCF alone for 4 days were more frequently (21%) in G0 (Fig.   2G ), more cells (0.6%) homed to the mouse BM (Fig. 2H ) and correspondingly more cells (27%) were detected with polarized domains ( We next confirmed the data obtained after ex vivo culture of human CD34+ cells by sorting cells in each phase of the cell cycle. As shown in a representative experiment (Fig. 2L) , the majority of cells in G0 showed domain polarity. In contrast, polarity was not detected in the majority of cycling cells in either the G1 or S/G2/M phases of the cell cycle. Figure 2M summarizes data from 3 independent donors, illustrating a disruption of domain polarity in actively cycling cells compared to quiescent cells. Consistent with this observation and the known cell adhesion properties of CD82 (15), an important component of the domain, we detected decreased osteoblastic adhesion in vitro when
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Polarized membrane domains are functionally important for homing and engraftment
We previously showed that cholesterol-and cytoskeletal-based processes are important for the polarized distribution of HSPC surface components (12) . When HSPC were exposed to the cholesterol-sequestering agent, methyl-β-cyclodextrin (MβCD), polarity of CD82 (Fig. 3A-B ) and other surface molecules normally enriched in the polarized domain (12) was disrupted, and the components of the domain were redistributed into punctuate clusters across the membrane. To better understand the significance of polarity of these surface markers for homing and engraftment, we disrupted the polarized membrane domains on normal non-cultured human CD34+ cells by exposure to 10mM MβCD for 30 minutes before transplantation into NSG mice.
Human CD34+ cells in the control group were exposed to vehicle alone for 30 minutes. For homing studies, 1x10 6 human CD34+ cells from 3 independent healthy donors were transplanted per mouse, and homing of the cells was analyzed in the BM, peripheral blood, spleen, lungs and liver of the animals 16 hours after transplantation. In the vehicle control group (Fig. 3C) , an average of 0.78% human CD34+ cells were detected in the mouse BM compared to 0.32% in the MβCD-treated group (Fig. 3C) . No transplanted cells were detected in the peripheral blood or other tissues analyzed in both control and MβCD groups with a detection limit of 0.1% (data not shown).
For engraftment studies, 1x10 4 (Fig. 3D) , suggesting that the polarized membrane domain is important for engraftment of long-term repopulating cells.
We next evaluated whether disruption of CD82 specifically on CD34+ cells using function-blocking antibodies would impact the homing process in NSG mice. CD34+ cells incubated with CD82 antibodies showed a ~2-fold decrease in homing (Fig. 3E) compared to control cells incubated with isotype antibodies. Similarly, we detected a 2.5-fold decrease in osteoblastic adhesion when cells were incubated with CD82 antibodies compared to the control group (Fig. 3F ). This observed decrease in homing and adhesion was not due to CD82 antibody effects on membrane domain organization and polarity (Supplemental Figures 3A-B) , or to changes in cell cycle status (Supplemental Figure   3C ), or in expression of other surface markers known to be important for HSPC homing, Figure 3D) . Similarly, CD82
antibodies had no impact on cell viability and did not result in an increase in CD82 internalization (data not shown). We speculate that CD82 antibody treatment disrupts homing and adhesion by blocking CD82 interacting proteins critical to these processes.
Taken together, these data suggest that an intact CD82-enriched polarized membrane domain is necessary for optimal homing of normal human CD34+ cells to, and adhesion within, the BM microenvironment.
Loss of membrane domain polarity in blast cells from leukemic patients
We next investigated whether polarized membrane domains could be found on blast cells from patients with AML (n=5), CML (n=1), and ALL (n=1). While approximately half of the HSPC from healthy donors showed domain polarity (average 47%, range 30-63%), the majority of blast cells from leukemic patients (>95% CD34+ cells in myeloid leukemias) lacked domain polarity (average 12%, range 0-26%) (Fig. 4A) . We hypothesized that the decreased percentage of leukemic blasts with polarized domains may be related to increased cell cycling. Compared to a healthy donor with 72% of CD34+ cells in the G0 phase of the cell cycle (Fig. 4B) and 60% of cells with polarized domains (Fig. 4C) , only 22% of cells were quiescent in a patient with AML (Fig. 4D) , and correspondingly the percentage of leukemic blasts with polarized domains was lower (24%, Fig. 4E ). Similar results were obtained with CD34+ cells derived from a patient diagnosed with CML blast crisis (Fig. 4F-G) . Interestingly, in a patient with ALL, no leukemic blasts were detected in the G0 phase of the cell cycle (Fig. 4H) and likewise no cells with a polarized domain were identified (Fig. 2I) . These data indicate a loss of membrane domain polarity in actively cycling blast cells from patients with AML, CML
and ALL, similar to actively cycling normal HSPC after ex vivo culture. Consistent with these data, leukemic blasts showed decreased abilities to adhere to osteoblasts in vitro compared to quiescent HSPC (Fig. 2N ). Leukemic blasts (Fig. 4J, control) also exhibited decreased homing in NSG mice compared to untreated, normal CD34+ cells (Fig. 3C, control, p=0.0000002), but showed similar homing capacity to normal CD34+ cells treated with MβCD (Fig. 3C, MβCD, p=0.12) . Exposure of leukemic blasts to MβCD had no impact on their homing ability, consistent with the absence of a polarized membrane domain on the majority of these cells prior to MβCD treatment (Fig. 4J, MβCD) .
DISCUSSION
In this paper, we show that polarity of membrane domains enriched in molecules known to be important for adhesion to the microenvironment, namely the tetraspanin CD82, is required for efficient homing and engraftment of normal HSPC to the BM. In contrast to normal non-cultured HSPC, the majority of blast cells from patients diagnosed with AML, CML and ALL were actively cycling and correspondingly Leukemic Cells * 60% CD82 polarity 24% CD82 polarity 10% CD82 polarity 0% CD82 polarity
